diquafosol has been researched along with cyclosporine in 11 studies
| Studies (diquafosol) | Trials (diquafosol) | Recent Studies (post-2010) (diquafosol) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
|---|---|---|---|---|---|
| 126 | 38 | 92 | 30,547 | 3,802 | 6,558 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Bremond-Gignac, D; Gicquel, JJ | 1 |
| Choi, W; Kim, N; Yang, JM; Yoon, KC | 1 |
| Ahn, BN; Kim, CE; Lee, H; Yang, J | 1 |
| Kang, S; Kim, CE; Kim, K; Kleinman, HK; Ousler, GW; Sosne, G; Yang, J | 1 |
| Ji, YW; Kang, HG; Kim, HC; Lee, HK; Moon, I; Noh, H; Song, JS; Yeo, A | 1 |
| Choi, CY; Chung, TY; Kim, EC; Kim, HK; Kim, HS; Kim, JY; Kim, MK; Kim, TI; Lee, DH; Lee, HK; Park, CH; Song, JS; Yoon, KC | 2 |
| Choi, YH; Kim, DH; Kim, MK; Kim, Y; Paik, HJ | 1 |
| Choi, CY; Ji, YW; Kim, HM; Kim, HS; Kim, KP; Kim, MJ; Lee, HK; Oh, JW; Ryu, SY; Seo, KY; Song, JS; Yeo, A | 1 |
| Baek, J; Kim, EC; Kim, HS; Kim, MS; Lee, JY; So, HR | 1 |
| Jia, F; Jiang, L; Jin, H; Li, Z; Xu, W; Zhao, X | 1 |
4 trial(s) available for diquafosol and cyclosporine
| Article | Year |
|---|---|
Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Conjunctiva; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Lubricant Eye Drops; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides; Young Adult | 2019 |
Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
Topics: Administration, Topical; Adult; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Emulsions; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Nanotechnology; Polyphosphates; Prospective Studies; Single-Blind Method; Tears; Treatment Outcome; Uracil Nucleotides | 2019 |
Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
Topics: Administration, Topical; Conjunctiva; Cornea; Cyclosporine; Dose-Response Relationship, Drug; Dry Eye Syndromes; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Proteome; Single-Blind Method; Tears; Treatment Outcome; Uracil Nucleotides | 2019 |
A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Prospective Studies | 2023 |
7 other study(ies) available for diquafosol and cyclosporine
| Article | Year |
|---|---|
Emerging treatments for dry eye: some like it hot, while others may prefer a good stimulation.
Topics: Animals; Cyclosporine; Dry Eye Syndromes; Humans; Hyaluronic Acid; Hyperthermia, Induced; Immunosuppressive Agents; Massage; Ophthalmic Solutions; Polyphosphates; Tears; Uracil Nucleotides | 2013 |
Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Cyclosporine; Dry Eye Syndromes; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Polyphosphates; Prospective Studies; Purinergic P2Y Receptor Agonists; Tears; Uracil Nucleotides | 2015 |
Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Histocytochemistry; Hyaluronic Acid; Mice; Ophthalmic Solutions; Peptides; Polyphosphates; Treatment Outcome; Uracil Nucleotides | 2017 |
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Topics: Animals; Conjunctiva; Cornea; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Female; Goblet Cells; Humans; Inflammation Mediators; Lacrimal Apparatus; Male; Mice; Mice, Inbred NOD; Mucins; Ophthalmic Solutions; Phenylalanine; Polyphosphates; Prescription Drugs; Scopolamine; Sulfones; Tears; Thymosin; Treatment Outcome; Uracil Nucleotides | 2018 |
Comparison of Ocular Surface Mucin Expression After Topical Ophthalmic Drug Administration in Dry Eye-Induced Mouse Model.
Topics: Administration, Topical; Alanine; Animals; Anti-Inflammatory Agents; Cyclosporine; Disease Models, Animal; Dry Eye Syndromes; Epithelium, Corneal; Female; Inflammation; Mice; Mice, Inbred C57BL; Mucins; Ophthalmic Solutions; Polyphosphates; Quinolones; Uracil Nucleotides | 2018 |
Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
Topics: Adult; Aged; Cornea; Cross-Sectional Studies; Cyclosporine; Dry Eye Syndromes; Female; Fluorescein; Fluorescent Dyes; Humans; Immunosuppressive Agents; Male; Middle Aged; Ophthalmic Solutions; Oxidants, Photochemical; Ozone; Polyphosphates; Prospective Studies; Tears; Uracil Nucleotides | 2019 |
Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye.
Topics: Cyclosporine; Dry Eye Syndromes; Humans; Matrix Metalloproteinase 9; Uracil Nucleotides | 2023 |